Pemphigus

Pemphigus is a group of autoimmune blistering diseases affecting the skin and mucous membranes of dogs and cats, characterized by acantholysis (loss of cell-to-cell adhesion) of keratinocytes, leading to the formation of intraepidermal clefts and vesicles. The disease results from autoantibodies directed against desmosomal proteins, primarily desmogleins, which are critical components of the desmosome, a cell junction that provides mechanical strength to the epidermis. In veterinary medicine, the most common form is pemphigus foliaceus (PF), followed by pemphigus vulgaris (PV), and less commonly, pemphigus erythematosus (PE), pemphigus vegetans, and paraneoplastic pemphigus. The clinical presentation varies from pustular and crusting dermatoses (PF) to severe ulcerative lesions of the oral cavity and mucocutaneous junctions (PV). The disease is chronic and often requires long-term immunosuppressive therapy. Systemic involvement is rare but can occur in severe cases, particularly with secondary bacterial infections or electrolyte imbalances due to extensive skin loss.

The exact etiology of pemphigus is not fully understood, but it is considered an autoimmune disease with a multifactorial pathogenesis. Genetic predisposition plays a significant role, with certain breeds being overrepresented, such as Akita, Chow Chow, Bearded Collie, and Doberman Pinscher for PF. Environmental triggers may include ultraviolet light exposure, drugs (e.g., cephalosporins, penicillins, sulfonamides, methimazole, and phenylbutazone), vaccines, and chronic inflammatory skin conditions. In some cases, pemphigus has been associated with underlying neoplasia (paraneoplastic pemphigus) or other autoimmune diseases. The autoimmune response is mediated by autoreactive T cells that stimulate B cells to produce pathogenic autoantibodies (IgG) against desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3). In PF, antibodies target Dsg1, which is expressed predominantly in the superficial epidermis, whereas in PV, antibodies target Dsg3, which is expressed in the basal and suprabasal layers. The binding of autoantibodies to desmogleins activates intracellular signaling pathways, leading to the release of proteases (e.g., plasminogen activator) that degrade desmosomal cadherins, resulting in acantholysis. Additionally, complement activation and recruitment of inflammatory cells contribute to the tissue damage.

Pemphigus is an uncommon disease in dogs and cats, with an estimated incidence of less than 1% of all dermatological cases. PF is the most common autoimmune skin disease in dogs, accounting for approximately 1-2% of all canine skin diseases. It can occur at any age, but middle-aged to older animals are more commonly affected (mean age 4-6 years in dogs, 5-7 years in cats). No sex predilection is consistently reported, though some studies suggest a slight female predominance. Breed predispositions include Akita, Chow Chow, Bearded Collie, Doberman Pinscher, Finnish Spitz, and Newfoundland for PF; for PV, breeds such as the German Shepherd, Collie, and Shetland Sheepdog may be at higher risk. In cats, PF is the most common autoimmune skin disease, with no strong breed predilection, but it may be more common in domestic shorthair cats. Geographic variation is not well-documented, but ultraviolet radiation may exacerbate lesions in sun-exposed areas, suggesting a higher prevalence in sunny climates. There is no known sex or age predilection for PV, but it is rarer than PF.

The pathophysiology of pemphigus involves a type II hypersensitivity reaction (antibody-mediated cytotoxicity). Autoantibodies (IgG) bind to desmogleins on the surface of keratinocytes, leading to acantholysis. The binding of antibodies to desmoglein 1 (in PF) or desmoglein 3 (in PV) triggers intracellular signaling cascades, including activation of p38 mitogen-activated protein kinase (MAPK) and protein kinase C, which lead to phosphorylation of desmoglein and its internalization from the cell membrane. This results in the loss of cell-cell adhesion and the formation of intraepidermal clefts. In PF, the cleavage occurs in the superficial layers (stratum granulosum and stratum spinosum), leading to the formation of pustules that are often subcorneal. In PV, the cleavage occurs in the suprabasal layer, resulting in deep vesicles and ulcers. The acantholytic cells are rounded, basophilic keratinocytes that are characteristic on cytology. Complement activation and recruitment of neutrophils and eosinophils contribute to the inflammatory response, leading to the formation of pustules and crusts. In PV, the lesions are more severe due to the deeper location of the split, and the loss of the epidermal barrier predisposes to secondary bacterial infections and fluid loss. The disease is chronic and may be exacerbated by stress, intercurrent illness, or drug administration.

Predisposing factors for pemphigus include genetic susceptibility, as evidenced by breed predispositions and familial occurrence. Environmental factors such as ultraviolet light exposure can trigger or exacerbate lesions, particularly in sun-exposed areas (e.g., face, ears, dorsum). Drug-induced pemphigus has been reported with certain medications, including antibiotics (e.g., ampicillin, cephalosporins, sulfonamides), antithyroid drugs (methimazole), and nonsteroidal anti-inflammatory drugs (phenylbutazone). Vaccination has been implicated as a trigger in some cases, possibly due to immune stimulation. Concurrent diseases, such as hypothyroidism, hyperadrenocorticism, or other autoimmune disorders, may increase the risk. Stress, both physical and emotional, can precipitate flares. In cats, chronic feline immunodeficiency virus (FIV) or feline leukemia virus (FeLV) infection may be a risk factor. Additionally, the use of topical medications or flea products containing certain chemicals may trigger the disease in susceptible individuals.

Clinical signs vary depending on the type of pemphigus. In pemphigus foliaceus (PF), the most common form, lesions are typically pustular and crusting, initially appearing on the face (especially the bridge of the nose, periocular area, and pinnae) and footpads. The pustules are often transient and rupture easily, leaving erosions, crusts, and alopecia. In dogs, the lesions may become generalized, affecting the trunk and limbs. In cats, PF often presents with lesions on the face, ears, and footpads, and may also involve the nipples and nail beds. Pruritus is variable but can be intense. Systemic signs such as fever, lethargy, and anorexia may occur, especially if secondary bacterial infection is present. In pemphigus vulgaris (PV), the primary lesions are vesicles and bullae that rapidly rupture, leading to painful ulcers. The oral cavity (gingiva, tongue, palate) and mucocutaneous junctions (lips, nostrils, eyelids, vulva, prepuce) are commonly affected. Skin lesions may also occur, but are less common than in PF. PV is often more severe, with significant pain, ptyalism, dysphagia, and reluctance to eat. Secondary bacterial infections are common, and the disease can be life-threatening if not treated promptly. Pemphigus erythematosus (PE) is considered a benign variant of PF, with lesions limited to the face and ears, and is often exacerbated by sun exposure. It may be associated with a positive antinuclear antibody (ANA) test, suggesting a possible overlap with systemic lupus erythematosus.

Differential diagnoses for pemphigus foliaceus include bacterial pyoderma (superficial), dermatophytosis, demodicosis, and other pustular dermatoses such as subcorneal pustular dermatosis, drug eruptions, and eosinophilic pustulosis. Bacterial pyoderma is characterized by the presence of bacteria on cytology and a positive response to antibiotics. Dermatophytosis can be ruled out by fungal culture or PCR. Demodicosis is diagnosed by skin scrapings. Subcorneal pustular dermatosis is a rare condition with sterile pustules, but histopathology shows a subcorneal pustule without acantholysis. Drug eruptions may mimic PF but have a history of recent drug administration. For pemphigus vulgaris, differentials include autoimmune diseases such as bullous pemphigoid, erythema multiforme, toxic epidermal necrolysis, and systemic lupus erythematosus. Bullous pemphigoid is characterized by subepidermal vesicles and autoantibodies against basement membrane components. Erythema multiforme and toxic epidermal necrolysis are immune-mediated diseases with epidermal necrosis and often have a history of drug exposure. Systemic lupus erythematosus can present with oral ulcers and skin lesions, but is associated with positive ANA and other systemic signs. Other differentials include mucocutaneous candidiasis, viral infections (e.g., calicivirus in cats), and thermal or chemical burns. Definitive diagnosis requires histopathology and immunopathology.

The diagnostic algorithm for pemphigus begins with a thorough history and physical examination, focusing on the distribution and morphology of lesions. The presence of pustules, crusts, erosions, and ulcers, especially on the face, ears, footpads, and oral cavity, raises suspicion. The next step is cytological evaluation of intact pustules or the undersurface of crusts. Cytology typically reveals acantholytic keratinocytes (rounded, basophilic cells with a large nucleus and condensed cytoplasm) and neutrophils, with or without eosinophils. The absence of bacteria and the presence of acantholytic cells support the diagnosis. If cytology is inconclusive, a skin biopsy is indicated. Multiple biopsy samples should be taken from early, intact pustules or vesicles, as older lesions may show secondary changes. Histopathology is the gold standard for diagnosis. In PF, histopathology shows subcorneal pustules with acantholytic keratinocytes and neutrophils. In PV, suprabasal clefts with acantholytic cells and a mixed inflammatory infiltrate are seen. Direct immunofluorescence (DIF) or immunohistochemistry (IHC) can be performed on frozen or paraffin-embedded tissue to detect intercellular IgG and/or complement (C3) deposition in the epidermis. Indirect immunofluorescence (IIF) on serum can detect circulating autoantibodies, but is less commonly used in veterinary medicine. Additional tests may include complete blood count, serum biochemistry, urinalysis, and skin culture to rule out secondary infections. In cases of suspected drug-induced pemphigus, withdrawal of the offending drug may be diagnostic. For paraneoplastic pemphigus, a thorough search for underlying neoplasia is warranted.

Laboratory findings in pemphigus are often nonspecific but may reflect systemic inflammation or secondary infections. Complete blood count may show leukocytosis with neutrophilia and a left shift, particularly in cases with secondary bacterial pyoderma. Eosinophilia may be present in some cases, especially in cats. Serum biochemistry may reveal hypoalbuminemia due to chronic inflammation or protein loss through skin lesions, and elevated globulins due to chronic antigenic stimulation. In severe cases with extensive skin involvement, electrolyte imbalances (e.g., hypokalemia, hyponatremia) may occur due to fluid loss. Liver enzymes may be mildly elevated due to systemic inflammation or drug therapy. Urinalysis is usually unremarkable unless there is concurrent urinary tract infection. Specific biomarkers such as antinuclear antibody (ANA) may be positive in some cases of pemphigus erythematosus, but are typically negative in PF and PV. Serology for infectious diseases (e.g., FeLV, FIV in cats) may be performed to rule out underlying immunosuppression. Cytology of pustules is a key laboratory finding, demonstrating acantholytic cells. Histopathology is the definitive diagnostic test, and direct immunofluorescence can be performed on biopsy samples to demonstrate intercellular immunoglobulin deposition. In some referral centers, ELISA or immunoblotting can detect circulating autoantibodies against desmogleins, but these tests are not widely available.

Imaging is not typically used in the diagnosis of pemphigus, as the disease is primarily cutaneous. However, in cases of suspected paraneoplastic pemphigus, imaging modalities such as thoracic radiography, abdominal ultrasonography, or computed tomography (CT) may be indicated to search for underlying neoplasia (e.g., lymphoma, thymoma). Thoracic radiography can reveal mediastinal masses or pulmonary metastases. Abdominal ultrasonography may identify splenic, hepatic, or renal masses. CT and MRI provide more detailed anatomical information and are useful for staging. In cases with severe oral lesions, dental radiography may be performed to rule out dental disease as a primary cause. Echocardiography is not indicated unless there is suspicion of cardiac involvement, which is rare. Overall, imaging plays a supportive role in the diagnostic workup, primarily to rule out concurrent diseases or identify paraneoplastic causes.

Cytology: Fine-needle aspiration of intact pustules or impression smears of the undersurface of crusts are highly diagnostic. The hallmark finding is the presence of acantholytic keratinocytes, which are large, round to oval cells with a central nucleus and deeply basophilic cytoplasm. They may be present singly or in clusters. Neutrophils are the predominant inflammatory cells, but eosinophils may also be seen, especially in cats. Bacteria are typically absent unless secondary infection is present. The presence of acantholytic cells in the absence of bacteria strongly supports pemphigus. Histopathology: Skin biopsy is the gold standard. For PF, early pustules are subcorneal or intragranular, containing acantholytic keratinocytes and neutrophils. The epidermis may show spongiosis and mild acanthosis. For PV, the cleft is suprabasal, with acantholytic cells and a mixed inflammatory infiltrate (neutrophils, eosinophils, lymphocytes). The dermis may show perivascular inflammation. Direct immunofluorescence (DIF) on frozen sections demonstrates intercellular deposition of IgG and/or C3 in the epidermis. Immunohistochemistry (IHC) using anti-IgG antibodies can be performed on formalin-fixed tissue. Special stains such as periodic acid-Schiff (PAS) may be used to rule out fungal infections. Histopathology is essential to differentiate pemphigus from other pustular or vesicular diseases.

Treatment of pemphigus aims to suppress the autoimmune response and manage clinical signs. The mainstay of therapy is immunosuppressive doses of glucocorticoids, such as prednisone or prednisolone. In dogs, the initial dose is typically 1-2 mg/kg PO q12h, while in cats, prednisolone is preferred at 2-4 mg/kg PO q24h or divided q12h. Once remission is achieved (usually within 2-4 weeks), the dose is gradually tapered over several months to the lowest effective dose. In severe or refractory cases, additional immunosuppressive agents are used as adjunctive therapy. Azathioprine is commonly used in dogs at 2 mg/kg PO q24h, but is contraindicated in cats due to severe bone marrow suppression. Chlorambucil is used in cats at 0.1-0.2 mg/kg PO q24h or q48h. Cyclosporine (Atopica) is effective in both dogs and cats at 5-10 mg/kg PO q24h. Mycophenolate mofetil is another option at 10-20 mg/kg PO q12h in dogs. In cases of severe, life-threatening disease, pulse therapy with intravenous methylprednisolone (10-20 mg/kg IV q24h for 1-3 days) may be used. Topical therapy with glucocorticoids (e.g., hydrocortisone aceponate) may be helpful for localized lesions. Secondary bacterial infections should be treated with appropriate antibiotics (e.g., cephalexin 22 mg/kg PO q12h for 3-4 weeks). Supportive care includes wound management, nutritional support, and fluid therapy if needed. In drug-induced pemphigus, withdrawal of the offending drug is essential. For paraneoplastic pemphigus, treatment of the underlying neoplasia is critical. Regular monitoring of complete blood count, serum biochemistry, and urine analysis is necessary to detect adverse effects of immunosuppressive therapy.

The prognosis for pemphigus varies depending on the type and severity. Pemphigus foliaceus generally has a good to guarded prognosis, with many animals achieving remission with appropriate therapy. However, the disease is chronic and often requires lifelong treatment. Some animals may experience relapses, especially if therapy is tapered too quickly or if triggers are present. The prognosis for pemphigus vulgaris is more guarded, as it is more severe and can be life-threatening due to extensive ulceration and secondary infections. With aggressive immunosuppressive therapy, remission can be achieved in many cases, but the risk of complications and drug side effects is higher. Pemphigus erythematosus has a good prognosis, as it is often controlled with topical therapy and sun avoidance. Negative prognostic indicators include severe systemic signs, poor response to initial therapy, and the development of secondary infections. The mortality rate for PV is reported to be up to 30-40% in some studies, but with modern treatment, it is lower. Long-term monitoring is essential to adjust therapy and manage side effects.

Follow-up care for pemphigus involves regular re-evaluations to monitor response to therapy and adjust drug dosages. Initially, re-checks should be performed every 2-4 weeks until remission is achieved. At each visit, a complete physical examination, including assessment of skin lesions, should be performed. Laboratory monitoring includes complete blood count, serum biochemistry, and urinalysis to detect adverse effects of immunosuppressive drugs (e.g., bone marrow suppression, hepatotoxicity, nephrotoxicity). For animals on azathioprine, CBC should be checked every 2 weeks for the first 2 months, then monthly. For cyclosporine, blood pressure and renal function should be monitored. Once remission is achieved, the glucocorticoid dose is tapered gradually over 2-4 months. The goal is to find the lowest effective dose to maintain remission. If the animal remains stable, re-checks can be extended to every 3-6 months. Owners should be educated to monitor for signs of relapse, such as new pustules or ulcers, and to avoid known triggers (e.g., sun exposure, stress). In cases of drug-induced pemphigus, the offending drug should be permanently avoided. Long-term management may include the use of adjunctive immunosuppressive agents to reduce the glucocorticoid dose. Regular communication with the owner is essential to ensure compliance and early detection of complications.

Pearls: 1. Cytology of intact pustules is a quick and inexpensive diagnostic tool; the presence of acantholytic cells is highly suggestive of pemphigus. 2. In cats, pemphigus foliaceus often presents with lesions on the face, ears, and footpads, and may be mistaken for eosinophilic granuloma complex. 3. Early and aggressive immunosuppressive therapy improves the chances of remission. 4. In dogs, azathioprine is a valuable adjunctive agent, but it takes 3-4 weeks to reach full effect; therefore, glucocorticoids are essential initially. 5. In cats, chlorambucil is preferred over azathioprine due to the risk of fatal bone marrow suppression. 6. Always rule out secondary bacterial pyoderma, as it can complicate the clinical picture and require antibiotic therapy. 7. Sun exposure can exacerbate lesions in pemphigus erythematosus; advise owners to limit sun exposure. Pitfalls: 1. Do not rely solely on cytology; histopathology is necessary for definitive diagnosis. 2. Avoid using topical corticosteroids alone for generalized disease; systemic therapy is required. 3. Do not taper immunosuppressive therapy too quickly, as this can lead to relapse. 4. Be cautious with the use of NSAIDs or other drugs that may trigger pemphigus. 5. In cats, never use azathioprine due to severe toxicity. 6. Do not overlook the possibility of paraneoplastic pemphigus; if the disease is refractory, investigate for underlying neoplasia. 7. Monitor for adverse effects of immunosuppressive drugs, especially bone marrow suppression and hepatotoxicity.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended for pemphigus:

1. Glucocorticoids: - Prednisone (dogs): 1-2 mg/kg PO q12h for 2-4 weeks, then taper gradually over 2-4 months to alternate-day therapy (e.g., 0.5-1 mg/kg q48h). - Prednisolone (cats): 2-4 mg/kg PO q24h or divided q12h; cats may require higher doses due to poor absorption of prednisone. - Methylprednisolone (pulse therapy): 10-20 mg/kg IV q24h for 1-3 days in severe cases.

2. Adjunctive immunosuppressants: - Azathioprine (dogs only): 2 mg/kg PO q24h, starting at the same time as glucocorticoids; onset of action 3-4 weeks. Reduce dose to q48h after remission. Monitor CBC and liver enzymes. - Chlorambucil (cats): 0.1-0.2 mg/kg PO q24h or q48h; onset 2-4 weeks. Monitor CBC. - Cyclosporine (dogs and cats): 5-10 mg/kg PO q24h; may take 4-6 weeks for full effect. Monitor blood pressure and renal function. - Mycophenolate mofetil (dogs): 10-20 mg/kg PO q12h; may be used as an alternative to azathioprine.

3. Topical therapy: - Hydrocortisone aceponate spray (Cortavance) applied to localized lesions q24h.

4. Antibiotics for secondary infections: - Cephalexin (dogs and cats): 22 mg/kg PO q12h for 3-4 weeks. - Amoxicillin-clavulanate (dogs and cats): 12.5-25 mg/kg PO q12h.

5. Supportive care: - Fluid therapy with balanced electrolyte solutions (e.g., Lactated Ringer's) for dehydrated patients. - Nutritional support with high-quality protein diet; consider feeding tubes if oral lesions prevent eating.

6. Monitoring: - CBC and serum biochemistry every 2-4 weeks during initial therapy, then every 3-6 months. - Urinalysis for proteinuria and urinary tract infections.

7. Contraindications and interactions: - Azathioprine is contraindicated in cats. - Glucocorticoids may cause polyuria, polydipsia, and increased risk of infections. - Cyclosporine may interact with ketoconazole, which increases its blood levels. - Avoid live vaccines in immunosuppressed animals.

Evidence-based literature on pemphigus in veterinary medicine is limited to retrospective studies, case series, and expert consensus. A landmark study by Olivry et al. (2009) established consensus guidelines for the treatment of canine pemphigus foliaceus, recommending a combination of glucocorticoids and adjunctive immunosuppressants. A retrospective study by Rosenkrantz (2010) reported that 70% of dogs with PF achieved remission with immunosuppressive therapy, with a median time to remission of 4 weeks. Another study by Bizikova et al. (2015) evaluated the use of cyclosporine in dogs with PF and found it to be effective as a monotherapy in some cases. In cats, a study by Preziosi et al. (2003) reported that chlorambucil combined with prednisolone was effective in controlling PF. A systematic review by Olivry and Bizikova (2013) summarized the evidence for various immunosuppressive agents, concluding that glucocorticoids remain the first-line treatment, with azathioprine and chlorambucil as effective adjuncts. There are no randomized controlled trials, but the consensus is that early aggressive therapy improves outcomes. The ACVIM consensus statement on autoimmune skin diseases (2015) provides guidelines for diagnosis and management. Overall, the evidence supports the use of immunosuppressive therapy, but the optimal protocols are based on clinical experience and expert opinion.